{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T23:27:51Z","timestamp":1793316471834,"version":"4.5.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T00:00:00Z","timestamp":1773705600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T00:00:00Z","timestamp":1773705600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Science and Technology Development Fund of Macau SAR","award":["0049\/2024\/AGJ"],"award-info":[{"award-number":["0049\/2024\/AGJ"]}]},{"DOI":"10.13039\/501100004733","name":"University of Macau","doi-asserted-by":"crossref","award":["MYRG-CRG2023-00007-ICMS-IAS"],"award-info":[{"award-number":["MYRG-CRG2023-00007-ICMS-IAS"]}],"id":[{"id":"10.13039\/501100004733","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Pharm"],"DOI":"10.1007\/s11096-026-02119-x","type":"journal-article","created":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T11:51:39Z","timestamp":1773748299000},"page":"1412-1423","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Comparison of treatment efficacy of targeted therapies approved in China for non-small cell lung cancer before and after the introduction of accelerated drug marketing registration procedures"],"prefix":"10.1007","volume":"48","author":[{"given":"Chenning","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liyang","family":"Lyu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yufan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingyi","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chihua","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanjia","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,17]]},"reference":[{"issue":"3","key":"2119_CR1","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1001\/jamaoncol.2021.6854","volume":"8","author":"GU Mehta","year":"2022","unstructured":"Mehta GU, de Claro RA, Pazdur R. Accelerated approval is not conditional approval: insights from international expedited approval programs. JAMA Oncol. 2022;8(3):335\u20136. https:\/\/doi.org\/10.1001\/jamaoncol.2021.6854.","journal-title":"JAMA Oncol"},{"issue":"17","key":"2119_CR2","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1001\/jama.2024.2396","volume":"331","author":"ITT Liu","year":"2024","unstructured":"Liu ITT, Kesselheim AS, Cliff ERS. Clinical benefit and regulatory outcomes of cancer drugs receiving accelerated approval. JAMA. 2024;331(17):1471\u20139. https:\/\/doi.org\/10.1001\/jama.2024.2396.","journal-title":"JAMA"},{"issue":"3","key":"2119_CR3","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/s1470-2045(23)00020-7","volume":"24","author":"DJ Benjamin","year":"2023","unstructured":"Benjamin DJ, Lythgoe MP. Modernising the US FDA\u2019s accelerated approval pathway. Lancet Oncol. 2023;24(3):203\u20135. https:\/\/doi.org\/10.1016\/s1470-2045(23)00020-7.","journal-title":"Lancet Oncol"},{"issue":"12","key":"2119_CR4","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1038\/nrd.2018.150","volume":"17","author":"L Xu","year":"2018","unstructured":"Xu L, Gao H, Kaitin KI, et al. Reforming China\u2019s drug regulatory system. Nat Rev Drug Discov. 2018;17(12):858\u20139. https:\/\/doi.org\/10.1038\/nrd.2018.150.","journal-title":"Nat Rev Drug Discov"},{"key":"2119_CR5","unstructured":"Measures for the Administration of Drug Registration. State Administration of Market Supervision and Administration. 2020. https:\/\/www.gov.cn\/zhengce\/zhengceku\/2020-04\/01\/content_5498012.htm. Accessed 01.05.2025."},{"issue":"5","key":"2119_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2025.104353","volume":"30","author":"Y Lan","year":"2025","unstructured":"Lan Y, Wang L, Lin X, et al. Evaluation of the implementation effectiveness of accelerated drug marketing registration procedures in China: lessons from the 2016-2024 regulatory review. Drug Discov Today. 2025;30(5):104353. https:\/\/doi.org\/10.1016\/j.drudis.2025.104353.","journal-title":"Drug Discov Today"},{"issue":"6","key":"2119_CR7","doi-asserted-by":"publisher","DOI":"10.1038\/d41573-021-00080-0","volume":"20","author":"G Li","year":"2021","unstructured":"Li G, Liu Y, Xie C, et al. Characteristics of expedited programmes for cancer drug approval in China. Nat Rev Drug Discov. 2021;20(6):416. https:\/\/doi.org\/10.1038\/d41573-021-00080-0.","journal-title":"Nat Rev Drug Discov"},{"issue":"7","key":"2119_CR8","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1038\/d41573-025-00070-6","volume":"24","author":"Y Gu","year":"2025","unstructured":"Gu Y, Jing R, Kaitin KI, et al. The impact of accelerated drug marketing registration procedures on the review and approval of new drugs in China. Nat Rev Drug Discov. 2025;24(7):492\u20133. https:\/\/doi.org\/10.1038\/d41573-025-00070-6.","journal-title":"Nat Rev Drug Discov"},{"key":"2119_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanwpc.2024.101238","volume":"52","author":"X Luo","year":"2024","unstructured":"Luo X, Xu Y, Du X, et al. Progress and challenges of confirmatory trials for cancer drugs granted conditional approval in China. Lancet Region Health West Pac. 2024;52:101238. https:\/\/doi.org\/10.1016\/j.lanwpc.2024.101238.","journal-title":"Lancet Region Health West Pac"},{"issue":"9","key":"2119_CR10","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1016\/S1470-2045(25)00329-8","volume":"26","author":"Y Zhang","year":"2025","unstructured":"Zhang Y, Chen D, Fu M, et al. Strength of evidence supporting cancer drug approvals in China between 2017 and 2021: a retrospective analysis. Lancet Oncol. 2025;26(9):1252\u201360. https:\/\/doi.org\/10.1016\/S1470-2045(25)00329-8.","journal-title":"Lancet Oncol"},{"issue":"3","key":"2119_CR11","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209\u201349. https:\/\/doi.org\/10.3322\/caac.21660.","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"2119_CR12","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.jncc.2024.01.006","volume":"4","author":"B Han","year":"2024","unstructured":"Han B, Zheng R, Zeng H, et al. Cancer incidence and mortality in China, 2022. J Natl Cancer Cent. 2024;4(1):47\u201353. https:\/\/doi.org\/10.1016\/j.jncc.2024.01.006.","journal-title":"J Natl Cancer Cent"},{"issue":"12","key":"2119_CR13","doi-asserted-by":"publisher","first-page":"3022","DOI":"10.1038\/s41591-023-02655-3","volume":"29","author":"Z Lu","year":"2023","unstructured":"Lu Z, Chen Y, Liu D, et al. The landscape of cancer research and cancer care in China. Nat Med. 2023;29(12):3022\u201332. https:\/\/doi.org\/10.1038\/s41591-023-02655-3.","journal-title":"Nat Med"},{"issue":"1","key":"2119_CR14","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/s41572-024-00551-9","volume":"10","author":"LEL Hendriks","year":"2024","unstructured":"Hendriks LEL, Remon J, Faivre-Finn C, et al. Non-small-cell lung cancer. Nat Rev Dis Primers. 2024;10(1):71. https:\/\/doi.org\/10.1038\/s41572-024-00551-9.","journal-title":"Nat Rev Dis Primers"},{"issue":"2","key":"2119_CR15","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1038\/s41571-024-00971-2","volume":"22","author":"F Zhou","year":"2025","unstructured":"Zhou F, Guo H, Xia Y, et al. The changing treatment landscape of EGFR-mutant non-small-cell lung cancer. Nat Rev Clin Oncol. 2025;22(2):95\u2013116. https:\/\/doi.org\/10.1038\/s41571-024-00971-2.","journal-title":"Nat Rev Clin Oncol"},{"key":"2119_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanwpc.2024.101090","volume":"49","author":"SY Maggie Liu","year":"2024","unstructured":"Maggie Liu SY, Jin ZY, Deng JY, et al. Drug development and evidence for lung cancer targeted therapy in Eastern Asia. Lancet Region Health West Pac. 2024;49:101090. https:\/\/doi.org\/10.1016\/j.lanwpc.2024.101090.","journal-title":"Lancet Region Health West Pac"},{"key":"2119_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2023.102177","volume":"63","author":"X Luo","year":"2023","unstructured":"Luo X, Du X, Huang L, et al. Evidence of pre-approval clinical trial supporting the granted conditional approval for novel cancer drugs in China between 2015 and 2022. EClinicalMedicine. 2023;63:102177. https:\/\/doi.org\/10.1016\/j.eclinm.2023.102177.","journal-title":"EClinicalMedicine"},{"issue":"6","key":"2119_CR18","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1200\/jco.21.01626","volume":"40","author":"AC Tan","year":"2022","unstructured":"Tan AC, Tan DSW. Targeted therapies for lung cancer patients with oncogenic driver molecular alterations. J Clin Oncol. 2022;40(6):611\u201325. https:\/\/doi.org\/10.1200\/jco.21.01626.","journal-title":"J Clin Oncol"},{"issue":"4","key":"2119_CR19","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1038\/s43018-021-00195-8","volume":"2","author":"A Passaro","year":"2021","unstructured":"Passaro A, J\u00e4nne PA, Mok T, et al. Overcoming therapy resistance in EGFR-mutant lung cancer. Nat Cancer. 2021;2(4):377\u201391. https:\/\/doi.org\/10.1038\/s43018-021-00195-8.","journal-title":"Nat Cancer"},{"issue":"7414","key":"2119_CR20","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JP Higgins","year":"2003","unstructured":"Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557\u201360. https:\/\/doi.org\/10.1136\/bmj.327.7414.557.","journal-title":"BMJ"},{"issue":"7109","key":"2119_CR21","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","volume":"315","author":"M Egger","year":"1997","unstructured":"Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629\u201334. https:\/\/doi.org\/10.1136\/bmj.315.7109.629.","journal-title":"BMJ"},{"issue":"11","key":"2119_CR22","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1002\/sim.1186","volume":"21","author":"JP Higgins","year":"2002","unstructured":"Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21(11):1539\u201358. https:\/\/doi.org\/10.1002\/sim.1186.","journal-title":"Stat Med"},{"issue":"11","key":"2119_CR23","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1002\/sim.1187","volume":"21","author":"SG Thompson","year":"2002","unstructured":"Thompson SG, Higgins JP. How should meta-regression analyses be undertaken and interpreted? Stat Med. 2002;21(11):1559\u201373. https:\/\/doi.org\/10.1002\/sim.1187.","journal-title":"Stat Med"},{"key":"2119_CR24","doi-asserted-by":"crossref","unstructured":"Higgins JP, Green S. Cochrane handbook for systematic reviews of interventions. Chichester, England; Hoboken. NJ: Wiley-Blackwell; 2008. ISBN: 9781119536628.","DOI":"10.1002\/9780470712184"},{"issue":"6","key":"2119_CR25","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1007\/s10198-023-01639-x","volume":"25","author":"DT Michaeli","year":"2024","unstructured":"Michaeli DT, Michaeli T, Albers S, et al. Special FDA designations for drug development: orphan, fast track, accelerated approval, priority review, and breakthrough therapy. Eur J Health Econ. 2024;25(6):979\u201397. https:\/\/doi.org\/10.1007\/s10198-023-01639-x.","journal-title":"Eur J Health Econ"},{"issue":"9","key":"2119_CR26","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1377\/hlthaff.2022.00119","volume":"41","author":"RG Frank","year":"2022","unstructured":"Frank RG, Shahzad M, Emanuel EJ. Accelerated approval of cancer drugs: no economic reward for drug makers that conduct confirmatory trials. Health Aff (Millwood). 2022;41(9):1273\u201380. https:\/\/doi.org\/10.1377\/hlthaff.2022.00119.","journal-title":"Health Aff (Millwood)"},{"issue":"9","key":"2119_CR27","doi-asserted-by":"publisher","first-page":"e385","DOI":"10.1016\/s1470-2045(23)00357-1","volume":"24","author":"A Cramer","year":"2023","unstructured":"Cramer A, S\u00f8rup FKH, Christensen HR, et al. Withdrawn accelerated approvals for cancer indications in the USA: what is the marketing authorisation status in the EU? Lancet Oncol. 2023;24(9):e385\u201394. https:\/\/doi.org\/10.1016\/s1470-2045(23)00357-1.","journal-title":"Lancet Oncol"},{"issue":"7","key":"2119_CR28","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1001\/jamainternmed.2019.0462","volume":"179","author":"B Gyawali","year":"2019","unstructured":"Gyawali B, Hey SP, Kesselheim AS. Assessment of the clinical benefit of cancer drugs receiving accelerated approval. JAMA Intern Med. 2019;179(7):906\u201313. https:\/\/doi.org\/10.1001\/jamainternmed.2019.0462.","journal-title":"JAMA Intern Med"},{"issue":"29","key":"2119_CR29","doi-asserted-by":"publisher","first-page":"3400","DOI":"10.1200\/jco.24.00581","volume":"42","author":"BJ Solomon","year":"2024","unstructured":"Solomon BJ, Liu G, Felip E, et al. Lorlatinib versus crizotinib in patients with advanced ALK-positive non-small cell lung cancer: 5-year outcomes from the Phase III CROWN study. J Clin Oncol. 2024;42(29):3400\u20139. https:\/\/doi.org\/10.1200\/jco.24.00581.","journal-title":"J Clin Oncol"},{"issue":"9","key":"2119_CR30","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1001\/jamaoncol.2016.0931","volume":"2","author":"H Kumar","year":"2016","unstructured":"Kumar H, Fojo T, Mailankody S. An appraisal of clinically meaningful outcomes guidelines for oncology clinical trials. JAMA Oncol. 2016;2(9):1238\u201340. https:\/\/doi.org\/10.1001\/jamaoncol.2016.0931.","journal-title":"JAMA Oncol"},{"issue":"7","key":"2119_CR31","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1001\/jamainternmed.2019.0583","volume":"179","author":"EY Chen","year":"2019","unstructured":"Chen EY, Raghunathan V, Prasad V. An overview of cancer drugs approved by the US Food and Drug Administration based on the surrogate end point of response rate. JAMA Intern Med. 2019;179(7):915\u201321. https:\/\/doi.org\/10.1001\/jamainternmed.2019.0583.","journal-title":"JAMA Intern Med"},{"key":"2119_CR32","unstructured":"Notice on Seeking Public Comments Once Again on the \"Procedures for the Review and Approval of Conditional Approval of Drug Marketing Applications (Trial) (Revised Draft for Comment)\" and Its Policy Interpretation. National Medical Products Administration. 2025. https:\/\/www.nmpa.gov.cn\/xxgk\/zhqyj\/zhqyjyp\/20250708155742138.html. Accessed 08.02.2026."},{"issue":"6","key":"2119_CR33","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1016\/s1470-2045(24)00152-9","volume":"25","author":"H Naci","year":"2024","unstructured":"Naci H, Zhang Y, Woloshin S, et al. Overall survival benefits of cancer drugs initially approved by the US Food and Drug Administration on the basis of immature survival data: a retrospective analysis. Lancet Oncol. 2024;25(6):760\u20139. https:\/\/doi.org\/10.1016\/s1470-2045(24)00152-9.","journal-title":"Lancet Oncol"},{"issue":"3","key":"2119_CR34","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1038\/s41571-023-00728-3","volume":"20","author":"Y Zhang","year":"2023","unstructured":"Zhang Y, Wagner AK, Guan X. Newly approved cancer drugs in China\u2014innovation and clinical benefit. Nat Rev Clin Oncol. 2023;20(3):135\u20136. https:\/\/doi.org\/10.1038\/s41571-023-00728-3.","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"2119_CR35","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1002\/cac2.12630","volume":"45","author":"L Tang","year":"2025","unstructured":"Tang L, Song Y, Zhang H, et al. Anti-tumor drug supervision in China from 2010 to 2024: the evolution and prospect of drug review standards. Cancer Commun. 2025;45(1):63\u20137. https:\/\/doi.org\/10.1002\/cac2.12630.","journal-title":"Cancer Commun"},{"key":"2119_CR36","unstructured":"Guidance for Clinical R&D of Antitumor Drugs Oriented by Clinical Value. Center for Drug Evaluation. 2021. https:\/\/www.cde.org.cn\/main\/news\/viewInfoCommon\/ef7bfde96c769308ad080bb7ab2f538e. Accessed 01.05.2025."},{"issue":"11","key":"2119_CR37","doi-asserted-by":"publisher","first-page":"799","DOI":"10.20892\/j.issn.2095-3941.2023.0360","volume":"20","author":"H Zhang","year":"2023","unstructured":"Zhang H, Liu S, Ge C, et al. Single-arm trials for domestic oncology drug approvals in China. Cancer Biol Med. 2023;20(11):799\u2013805. https:\/\/doi.org\/10.20892\/j.issn.2095-3941.2023.0360.","journal-title":"Cancer Biol Med"},{"key":"2119_CR38","unstructured":"Technical guidelines on the applicability of single-arm clinical trials for use in support of oncology drug marketing applications. Center for Drug Evaluation, National Medical Products Administration. 2023. https:\/\/www.cde.org.cn\/main\/news\/viewInfoCommon\/9f0c25dee6ba6781af809b36cf682eb6. Accessed 01.05.2025."},{"issue":"3","key":"2119_CR39","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.0380","volume":"4","author":"AK Herbrand","year":"2021","unstructured":"Herbrand AK, Schmitt AM, Briel M, et al. Association of supporting trial evidence and reimbursement for off-label use of cancer drugs. JAMA Netw Open. 2021;4(3):e210380. https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.0380.","journal-title":"JAMA Netw Open"},{"issue":"5","key":"2119_CR40","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1001\/jamainternmed.2018.8121","volume":"179","author":"AS Kesselheim","year":"2019","unstructured":"Kesselheim AS, Woloshin S, Lu Z, et al. Physicians\u2019 perspectives on FDA approval standards and off-label drug marketing. JAMA Intern Med. 2019;179(5):707\u20139. https:\/\/doi.org\/10.1001\/jamainternmed.2018.8121.","journal-title":"JAMA Intern Med"},{"key":"2119_CR41","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n1959","volume":"374","author":"B Gyawali","year":"2021","unstructured":"Gyawali B, Rome BN, Kesselheim AS. Regulatory and clinical consequences of negative confirmatory trials of accelerated approval cancer drugs: retrospective observational study. BMJ. 2021;374:n1959. https:\/\/doi.org\/10.1136\/bmj.n1959.","journal-title":"BMJ"}],"container-title":["International Journal of Clinical Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-026-02119-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11096-026-02119-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-026-02119-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T13:31:21Z","timestamp":1784035881000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11096-026-02119-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,17]]},"references-count":41,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["2119"],"URL":"https:\/\/doi.org\/10.1007\/s11096-026-02119-x","relation":{},"ISSN":["2210-7711"],"issn-type":[{"value":"2210-7711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,17]]},"assertion":[{"value":"25 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Ethics review and informed consent were waived because all analyzed data were derived from open-access repositories, aggregated clinical trial databases, and published literature that did not contain individual patient identifiers.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}]}}